Britanin Ameliorates Cerebral Ischemia-Reperfusion Injury by Inducing the Nrf2 Protective Pathway

Antioxidants and Redox Signaling

Volumn 27, Issue 11, 2017, Pages 754-768

  Wu, Guozhen ^a   Zhu, Lili ^b   Yuan, Xing ^a   Chen, Hao ^a   Xiong, Rui ^b   Zhang, Shoude ^b   Cheng, Hao ^a   Shen, Yunheng ^a   An, Huazhang ^a   Li, Tiejun ^a   Li, Honglin ^b   Zhang, Weidong ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Britanin; Keap1; Nrf2; ROS; stroke

Indexed keywords

ALPHA TOCOPHEROL; BRITANIN; CASPASE 3; CYSTEINE; GLUCOSE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LACTATE DEHYDROGENASE; MESSENGER RNA; NATURAL PRODUCT; NEUROPROTECTIVE AGENT; OXYGEN; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; BRITANNIN; LACTONE; NFE2L2 PROTEIN, RAT; SESQUITERPENE;

ALKYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN CELL CULTURE; BRAIN ISCHEMIA; BTB-POZ DOMAIN; CELL LYSATE; CELL VIABILITY; CONTROLLED STUDY; COVALENT BOND; CRYSTAL STRUCTURE; CYTOTOXICITY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HYDROGEN BOND; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MICHAEL ADDITION; MIDDLE CEREBRAL ARTERY OCCLUSION; MTT ASSAY; NEUROPROTECTION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUNEL ASSAY; UBIQUITINATION; X RAY CRYSTALLOGRAPHY; ANIMAL; CELL CULTURE; DRUG EFFECTS; GENE EXPRESSION REGULATION; HEK293 CELL LINE; HUMAN; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN ISCHEMIA; CELLS, CULTURED; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; LACTONES; NF-E2-RELATED FACTOR 2; RATS; REPERFUSION INJURY; SESQUITERPENES; SIGNAL TRANSDUCTION;

EID: 85028817942     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2016.6885     Document Type: Article

References (43)

1. Alfieri A, Srivastava S, Siow RC, Cash D, Modo M, Duchen MR, Fraser PA, Williams SC, and Mann GE. Sulforaphane preconditioning of the Nrf2/HO-1 defense pathway protects the cerebral vasculature against blood-brain barrier disruption and neurological deficits in stroke. Free Radic Biol Med 65: 1012-1022, 2013.
2. Apopa PL, He X, and Ma Q. Phosphorylation of Nrf2 in the transcription activation domain by casein kinase 2 (CK2) is critical for the nuclear translocation and transcription ac-Tivation function of Nrf2 in IMR-32 neuroblastoma cells. J Biochem Mol Toxicol 22: 63-76, 2008.
3. Battye TGG, Kontogiannis L, Johnson O, Powell HR, and Leslie AGW. iMOSFLM : A new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr D Biol Crystallogr 67: 271-281, 2011.
4. Bomprezzi R. Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: An overview. Ther Adv Neurol Disord 8: 20-30, 2015.
5. Chen H, Yoshioka H, Kim GS, Jung JE, Okami N, Sakata H, Maier CM, Narasimhan P, Goeders CE, and Chan PH. Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid Redox Signal 14: 1505-1517, 2011.
6. Chen Z-H, Saito Y, Yoshida Y, Sekine A, Noguchi N, and Niki E. 4-Hydroxynonenal induces adaptive response and enhances PC12 cell tolerance primarily through induction of thioredoxin reductase 1 via activation of Nrf2. J Biol Chem 280: 41921-41927, 2005.
7. Cleasby A, Yon J, Day PJ, Richardson C, Tickle IJ, Williams PA, Callahan JF, Carr R, Concha N, Kerns JK, Qi H, Sweitzer T, Ward P, Davies TG, and Xu E. Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO. PLoS One 9: e98896, 2014.
8. Crack PJ and Taylor JM. Reactive oxygen species and the modulation of stroke. Free Radic Biol Med 38: 1433-1444, 2005.
9. Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, and Diehl JA. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol 23: 7198-7209, 2003.
10. Dao VT, Casas AI, Maghzal GJ, Seredenina T, Kaludercic N, Robledinos-Anton N, Di Lisa F, Stocker R, Ghezzi P, Jaquet V, Cuadrado A, and Schmidt HH. Pharmacology and clinical drug candidates in redox medicine. Antioxid Redox Signal 23: 1113-1129, 2015.
11. Doyle KP, Simon RP, and Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology 55: 310-318, 2008.
12. Emsley P, Lohkamp B, Scott WG, and Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66: 486-501, 2010.
13. Gao L, Wang J, Sekhar KR, Yin H, Yared NF, Schneider SN, Sasi S, Dalton TP, Anderson ME, Chan JY, Morrow JD, and Freeman ML. Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. J Biol Chem282: 2529-2537, 2007.
14. Hong F, Sekhar KR, Freeman ML, and Liebler DC. Specific patterns of electrophile adduction trigger Keap1 Ubiquitination and Nrf2 activation. J Biol Chem 280: 31768-31775, 2005.
15. Huang H-C, Nguyen T, and Pickett CB. Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2. Proc Natl Acad Sci U S A 97: 12475-12480, 2000.
16. Ishii T. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in Macrophages. J Biol Chem 275: 16023-16029, 2000.
17. Itoh K, WakabayashiN, Katoh Y, Ishii T, IgarashiK, Engel JD, and Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-Terminal Neh2 domain. Genes Dev 13: 76-86, 1999.
18. Jiang Z-Y, Lu M-C, Yang T-T, Xi M-Y, Xu X-L, Guo X-K, Zhang X-J, You Q-D, and Sun H-P. Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis. J Med Chem 57: 2736-2745, 2014.
19. Kajta M, Lasoń W, and Kupiec T. Effects of estrone on Nmethyl-D-Aspartic acid-And staurosporine-induced changes in caspase-3-like protease activity and lactate dehydrogenaserelease: Time-And tissue-dependent effects in neuronal primary cultures. Neuroscience 123: 515-526, 2004.
20. Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, and ONeill GN. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebocontrolled phase IIb study. Lancet 372: 1463-1472, 2008.
21. Kobayashi M and Yamamoto M. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv Enzyme Regul 46: 113-140, 2006.
22. Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother 11: 1753-1763, 2010.
23. Lee J-M. Nrf2, a multi-organ protector? FASEB J 19: 1061-1066, 2005.
24. Lee J-M, Shih AY, Murphy TH, and Johnson JA. NF-E2-related Factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular Calcium in primary cortical neurons. J Biol Chem 278: 37948-37956, 2003.
25. Li J. Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells. Toxicol Sci 83: 313-328, 2004.
26. Longa EZ, Weinstein PR, Carlson S, and Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20: 84-91, 1989.
27. Luo Y, Yang X, Zhao S, Wei C, Yin Y, Liu T, Jiang S, Xie J, Wan X, Mao M, et al. Hydrogen sulfide prevents OGD/Rinduced apoptosis via improving mitochondrial dysfunction and suppressing an ROS-mediated caspase-3 pathway in cortical neurons. Neurochem Int 63: 826-831, 2013.
28. Marcotte D, Zeng W, Hus J-C, McKenzie A, Hession C, Jin P, Bergeron C, Lugovskoy A, Enyedy I, Cuervo H, Wang D, Atemanene C, Roechlin D, Vecchi M, Vivat V, Kraemer J, Winkler D, Hong V, Chao J, Lukashev M, and Silvian L. Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism. Bioorg Med Chem 21: 4011-4019, 2013.
29. Meloni BP, Meade AJ, Kitikomolsuk D, and Knuckey NW. Characterisation of neuronal cell death in acute and delayed in vitro ischemia (oxygen-glucose deprivation) models. J Neurosci Methods 195: 67-74, 2011.
30. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, NichollsRA, WinnMD, LongF, andVaginAA.REFMAC 5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 67: 355-367, 2011.
31. Nie L-Y, Qin J-J, Huang Y, Yan L, Liu Y-B, Pan Y-X, Jin H-Z, and Zhang W-D. Sesquiterpenoids from Inula lineariifolia inhibit nitric oxide production. J Nat Prod 73: 1117-1120, 2010.
32. Ogura T, Tong KI, Mio K, Maruyama Y, Kurokawa H, Sato C, and Yamamoto M. Keap1 is a forked-stem dimer structure with two large spheres enclosing the intervening, double glycine repeat, and C-Terminal domains. Proc Natl Acad Sci U S A 107: 2842-2847, 2010.
33. Qian Y, Guan T, Huang M, Cao L, li Y, Cheng H, Jin H, and Yu D. Neuroprotection by the soy isoflavone, genistein, via inhibition of mitochondria-dependent apoptosis pathways and reactive oxygen induced-NF-jB activation in a cerebral ischemia mouse model. Neurochem Int 60: 759-767, 2012.
34. Rojo AI, Sagarra MR de, and Cuadrado A. GSK-3b downregulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J Neurochem 105: 192-202, 2008.
35. Satoh T, Okamoto S-I, Cui J, WatanabeY, FurutaK, Suzuki M, Tohyama K, and Lipton SA. Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophillic phase II inducers. Proc Natl Acad Sci U S A 103: 768-773, 2006.
36. Schmidt HHHW, Stocker R, Vollbracht C, Paulsen G, Riley D, Daiber A, and Cuadrado A. Antioxidants in translational medicine. Antioxid Redox Signal 23: 1130-1143, 2015.
37. Shah ZA, Li R-C, Thimmulappa RK, Kensler TW, Yamamoto M, Biswal S, and Dore S. Role of reactive oxygen species in modulation of Nrf2 following ischemic reperfusion injury. Neuroscience 147: 53-59, 2007.
38. Surh Y-J, Kundu J, and Na H-K. Nrf2 as aMasterRedox Switch in Turning on the Cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med 74: 1526-1539, 2008.
39. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, and Sharp FR. A Semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 10: 290-293, 1990.
40. Wang G-W, Qin J-J, Cheng X-R, Shen Y-H, Shan L, Jin HZ, and Zhang W-D. Inula sesquiterpenoids: structural diversity, cytotoxicity and anti-Tumor activity. Expert Opin Investig Drugs 23: 317-345, 2014.
41. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, KeeganRM, Krissinel EB, LeslieAGW, andMcCoy A.Overview of theCCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67: 235-242, 2011.
42. Xu C. Mechanism of action of isothiocyanates: The induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation ofNrf2. Mol Cancer Ther 5: 1918-1926, 2006.
43. Zhao J, Kobori N, Aronowski J, and Dash PK. Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. Neurosci Lett 393: 108-112, 2006.